Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer

Pluard TJ, Sandin R, Parikh RC, Ward MA, Stansfield L, Nham T, Esterberg E, Cha-Silva AS, Shah B

ClinicoEconomics and Outcomes Research 2025, 17:247-264

Published Date: 26 March 2025